Clostridium Difficile News and Research

RSS

Clostridium difficile is a type of bacterium found in human and animal waste. Clostridium difficile is a common cause of diarrhea that occurs in hospitals. It can also cause diarrhea or other intestinal disorders in patients treated with antibiotics.

Health Canada approves VIBATIV for treating complicated skin and skin structure infections

Astellas Pharma Canada, Inc. announced today that Health Canada has approved VIBATIV(TM) (telavancin) for the treatment of adult patients with complicated skin and skin structure infections (cSSSI) caused by susceptible Gram-positive bacteria, including Staphylococcus aureus, both methicillin-resistant (MRSA) and methicillin-susceptible (MSSA) strains.

1 Oct 2009

Phase 1 clinical trial to test safety and activity of human MAB launched in India

MassBiologics of the University of Massachusetts Medical School today announced the beginning of a Phase 1 clinical trial, testing the safety and activity of a human monoclonal antibody (MAB) developed to neutralize the rabies virus.

1 Oct 2009

Automated SafetySurveillor system to detect healthcare-associated infections

The Premier healthcare alliance today announced that Bon Secours St. Francis Medical Center of Midlothian, Va., selected Premier’s SafetySurveillor® Web-based infection tracking and antimicrobial utilization tool. More than 270 hospitals use SafetySurveillor to help prevent healthcare-associated infections (HAIs) and optimize antibiotic use, thereby protecting patients more effectively while safely reducing hospital costs.

30 Sep 2009

Clostridium difficile's five genetic regions identified

Five genetic regions have been identified that are unique to the most virulent strain of Clostridium difficile (C. difficile), the hospital superbug. Researchers writing in BioMed Central's open access journal Genome Biology studied the genome of the bacterium, looking for genes relating to motility, antibiotic resistance and toxicity.

25 Sep 2009

Optimer's North American phase 3 Fidaxomicin study results presented at the 49th ICAAC

Optimer Pharmaceuticals, Inc. (Nasdaq: OPTR) today announced that new data highlighting fidaxomicin's (OPT-80) lower CDI recurrence rates and reduced risk of vancomycin-resistant enterococci (VRE) acquisition from Optimer's North American phase 3 study were presented at the 49th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) in San Francisco.

16 Sep 2009

FDA approves Theravance's VIBATIV for treating complicated skin and skin structure infections

Theravance, Inc. (NASDAQ: THRX) and Astellas Pharma US, Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved VIBATIV™ (telavancin) for the treatment of adult patients with complicated skin and skin structure infections (cSSSI) caused by susceptible Gram-positive bacteria, including Staphylococcus aureus, both methicillin-resistant (MRSA) and methicillin-susceptible (MSSA) strains.

14 Sep 2009

Recurrence of Clostridium difficile infection is a growing area of concern in hospitals

Arlington Medical Resources (AMR) and Decision Resources find that relapse or recurrence of infections is the most challenging aspect of treating Clostridium difficile infections in the hospital setting.

3 Sep 2009

Bioneutral Group holds scientific and business discussions with major health care companies

BioNeutral Group, Inc. (“BioNeutral”) (OTCBB:BONU), a specialty chemical technology based Life Science Company, announced discussions with four of the world’s largest health care companies.

25 Aug 2009

Norovirus controlled on cruise ship Marco Polo with vaporisation process by Activ8

The cruise ship Marco Polo, whose round-Britain cruise had to be cancelled because hundreds of passengers became ill with the vomiting bug Norovirus, has been totally disinfected by SitexOrbis' revolutionary infection control fogging service in just 5 hours at the Tilbury docks.

19 Aug 2009

New online tool to help nurses prevent the 10 "Never Events"

Elsevier, a world leader in healthcare and medical publishing and online solutions, today announced the availability of a new online tool within Mosby's Nursing Consult designed to help nurses prevent the 10 "Never Events" identified by the Centers for Medicare and Medicaid Services (CMS) in an October 2008 fact sheet.

10 Aug 2009

Phase 1 clinical trial starts for new antibody aimed at hepatitis C virus

Building upon a series of successful preclinical studies, researchers at MassBiologics of the University of Massachusetts Medical School (UMMS) today announced the beginning of a Phase 1 clinical trial, testing the safety and activity of a human monoclonal antibody they developed that can neutralize the Hepatitis C virus (HCV).

6 Aug 2009

Machine designed to reduce infections and cut back on expensive "disposables"

Johns Hopkins experts in applied physics, computer engineering, infectious diseases, emergency medicine, microbiology, pathology and surgery have unveiled a 7-foot-tall, $10,000 shower-cubicle-shaped device that automatically sanitizes in 30 minutes all sorts of hard-to-clean equipment in the highly trafficked hospital emergency department.

30 Jul 2009

Researchers expose the biology of Clostridium difficile transmission in mice

New research suggests that antibiotic treatment could be asymptomatically inducing the transmission of the healthcare-acquired infection, C. difficile, contributing to the outbreaks that have recently been widely reported in hospitals and other settings. A team of scientists have successfully mirrored the infection cycle of C. difficile by generating a 'mouse hospital' with conditions mimicking the human environment in which C. difficile is transmitted.

20 Jul 2009

Do viruses make bacteria more deadly?

In England and Wales, the national health statistics in 2007 showed that there were 8,324 death certificates which named Clostridium difficile. This is a bacterium which causes severe diarrhoea in humans and animals as the underlying cause of death, a 28% increase from 2006.

22 Jun 2009

Antibiotics diminish diversity of helpful gutmicrobes

It's common knowledge that a protective navy of bacteria normally floats in our intestinal tracts. Antibiotics at least temporarily disturb the normal balance. But it's unclear which antibiotics are the most disruptive, and if the full array of "good bacteria" return promptly or remain altered for some time.

18 Jun 2009

Hospital infection prevention resources cut

Hospitals are cutting staff, resources and education for infection prevention at a time when the prevalence of many healthcare-associated infections is increasing, according to a report released today by the Association for Professionals in Infection Control and Epidemiology (APIC).

9 Jun 2009

Old drug Auranofin may lead to new antibiotics

A mineral found at health food stores could be the key to developing a new line of antibiotics for bacteria that commonly cause diarrhea, tooth decay and, in some severe cases, death.

1 Jun 2009

Transmission of MRSA and Clostridium difficile through dogs

In a letter to the Editor of the Journal of Hospital Infection, published by Elsevier, S. Lefebvre and J.S. Weese from the University of Guelph in Canada describe a study that investigated whether MRSA and C.difficile could be passed between pet therapy dogs and patients.

7 May 2009

Optimer Pharmaceuticals receives production patent for Fidaxomicin

Optimer Pharmaceuticals, Inc. has announced that the United States Patent and Trademark Office issued a production patent (U.S. Patent No. 7,507,564) covering steps used in the manufacture of fidaxomicin, which is currently in its second Phase 3 clinical trial for the treatment of Clostridium difficile infection, or CDI.

13 Apr 2009

Targeted approach to kill specific disease-causing bacteria in the mouth

Research to develop a narrow-spectrum antibiotic that can target a particular species of bacteria without harming the other "good" bacteria present was described at the Society for General Microbiology meeting at Harrogate today (Thursday April 2).

1 Apr 2009